Device Modification Review Times Fall Behind In Canada, Australia, Japan
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers having difficulty defining "substantial change" when determining whether to submit product modification plans to regulatory authorities should formalize their internal decision-making processes, according to Guidant Regulatory Affairs Manager Gayle Johnson
You may also be interested in...
Australian Medical Device Framework Takes Effect; Reuse Is On Horizon
Sponsors of the 20% of CE-marked Class I, Class IIa and Class IIb devices randomly selected to undergo an audit by Australia's Therapeutic Goods Administration will pay additional fees under the country's new medical device framework, which took effect Oct. 4
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.